The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are increasing in both incidence and prevalence. A delay in correct diagnosis is common for these lesions. This reflects the absence of specific blood biomarkers to detect NENs. Measurement of the neuroendocrine secretory peptide Chromogranin A (CgA) is used, but is a single value, is non-specific and assay data are highly variable. To facilitate tumor detection, we developed a multi-transcript molecular signature for PCR-based blood analysis. NEN transcripts were identified by computational analysis of 3 microarray datasets: NEN tissue (n = 15), NEN peripheral blood (n = 7), and adenocarcinoma (n = 363 tumors). The candidate gene signature was examined in 130 blood samples (NENs: n = 63) and validated in two independent sets (Set 1 [n = 115, NENs: n = 72]; Set 2 [n = 120, NENs: n = 58]). Comparison with CgA (ELISA) was undertaken in 176 samples (NENs: n = 81). 51 significantly elevated transcript markers were identified. Gene-based classifiers detected NENs in independent sets with high sensitivity (85-98%), specificity (93-97%), PPV (95-96%) and NPV (87-98%). The AUC for the NEN gene-based classifiers was 0.95-0.98 compared to 0.64 for CgA (Z-statistic 6.97-11.42, p<0.0001). Overall, the gene-based classifier was significantly (χ(2) = 12.3, p<0.0005) more accurate than CgA. In a sub-analysis, pancreatic NENs and gastrointestinal NENs could be identified with similar efficacy (79-88% sensitivity, 94% specificity), as could metastases (85%). In patients with low CgA, 91% exhibited elevated transcript markers. A panel of 51 marker genes differentiates NENs from controls with a high PPV and NPV (>90%), identifies pancreatic and gastrointestinal NENs with similar efficacy, and confirms GEP-NENs when CgA levels are low. The panel is significantly more accurate than the CgA assay. This reflects its utility to identify multiple diverse biological components of NENs. Application of this sensitive and specific PCR-based blood test to NENs will allow accurate detection of disease, and potentially define disease progress enabling monitoring of treatment efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast unfolding of communities in large networks
Blondel, V. D., Guillaume, J.-L., Lambiotte, R., & Lefebvre, E. (2008) · Journal of Statistical Mechanics: Theory and Experiment · doi:10.1088/1742-5468/2008/10/p10008 · Cited by 21,424 · cited 1×
“We used the Louvain algorithm, a ‘‘greedy’’ method for iterative grouping of nodes into communities through modularity maximization [24], to partition the GEP-NEN network into 62 clusters with 800 and 3 genes in the largest and smallest clusters respectively ( Figure 2A ).”
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 1×
“Intheformer,this isusedinprognosis,identificationofmetastasisandrecurrence, predictionoftherapyresponseandmetastasis-freesurvivalfornode-negative,untreatedprimarycancers[6,7];forthelatter,utilityhas beendeterminedforstaging[8].”
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510 · cited 1×
“Although previously considered rare, gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are common (incidence: 3.6/100,000), occurring as frequently as testicular tumors, Hodgkin’s disease, gliomas and multiple myeloma [1] and are estimated to have a prevalence of 35/100,000 [2].”
InfluentialBustin, S. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250169 · Cited by 3,872 · cited 2×
“A consistent protocol for RNA isolation, cDNA synthesis and real-time PCR is considered appropriate to provide a stable platform for target and housekeeping gene analyses [57,62,63,66,67].”
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems
Bustin, S. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0290023 · Cited by 2,546 · cited 2×
“A consistent protocol for RNA isolation, cDNA synthesis and real-time PCR is considered appropriate to provide a stable platform for target and housekeeping gene analyses [57,62,63,66,67].”
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 1×
“Thirteen marker genes previously associated with GEP-NENs, either in our studies [11,12] or in others [16,27], were identified using queries of the Catalogue of Somatic Mutations in Cancer (COSMIC v60) database [28].”
A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules
Stuart, J. M., Segal, E., Koller, D., & Kim, S. K. (2003) · Science · doi:10.1126/science.1087447 · Cited by 2,256 · cited 1×
“…network does not attempt to identify ‘‘direct gene interactions’’ but rather contain ‘‘gene neighborhood relations’’ that are usually overlooked in conventional microarray analysis [22] and is used to identify genes that play distinct roles in a common pathway or biological process [23].”
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R
Langfelder, P., Zhang, B., & Horvath, S. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btm563 · Cited by 1,892
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748 · cited 4×
“CgA is constitutive component of neuroendocrine secretion, not proliferation, and therefore its use as a surrogate marker for tumor growth has obvious limitations [1].”
InfluentialSelf-citationSchmittgen, T. D., Zakrajsek, B. A., Mills, A. G., Gorn, V., Singer, M. J., & Reed, M. W. (2000) · Analytical Biochemistry · doi:10.1006/abio.2000.4753 · Cited by 1,035 · cited 1×
“In other studies, this has been demonstrated to have a low variability between runs ranging between 0–5% [62], have small coefficient of variations (CVs) for the cycling threshold (C T ) of 1–3% [63] and results in acceptable CVs for normalized data between 10–24% [64,65].”
Geometric Interpretation of Gene Coexpression Network Analysis
Horvath, S., & Dong, J. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000117 · Cited by 851 · cited 1×
“…network does not attempt to identify ‘‘direct gene interactions’’ but rather contain ‘‘gene neighborhood relations’’ that are usually overlooked in conventional microarray analysis [22] and is used to identify genes that play distinct roles in a common pathway or biological process [23].”
Hess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6861 · Cited by 721 · cited 1×
“Intheformer,this isusedinprognosis,identificationofmetastasisandrecurrence, predictionoftherapyresponseandmetastasis-freesurvivalfornode-negative,untreatedprimarycancers[6,7];forthelatter,utilityhas beendeterminedforstaging[8].”
Reubi, J. C., & Waser, B. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1184-3 · Cited by 592 · cited 1×
“, MEN-I) [71–73] between GEP-NENs and other NENs e.”
Parkinson, H., Kapushesky, M., Kolesnikov, N., Rustici, G., Shojatalab, M., Abeygunawardena, N., Berube, H., Dylag, M., Emam, I., Farne, A., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn889 · Cited by 422 · cited 1×
“Human cancer and normal tissue microarray datasets were obtained (ArrayExpress database [14]).”
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387 · cited 1×
“%) since CgA is elevated in a wide variety of diverse conditions [30,33,43].”
Self-citationValidation of a quantitative method for real time PCR kinetics
Liu, W., & Saint, D. A. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00478-3 · Cited by 359 · cited 1×
“A consistent protocol for RNA isolation, cDNA synthesis and real-time PCR is considered appropriate to provide a stable platform for target and housekeeping gene analyses [57,62,63,66,67].”
Lekanne Deprez, R. H., Fijnvandraat, A. C., Ruijter, J. M., & Moorman, A. F. M. (2002) · Analytical Biochemistry · doi:10.1016/s0003-2697(02)00021-0 · Cited by 338
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2056 · Cited by 304 · cited 1×
“The lack of sensitive and robust biomarkers to establish diagnosis, assess disease progress and monitor treatment efficacy has been identified as key unmet needs [3].”
Stridsberg, M., Öberg, K., Li, Q., Engström, U., & Lundqvist, G. (1995) · Journal of Endocrinology · doi:10.1677/joe.0.1440049 · Cited by 278
Zippelius, A., Kufer, P., Honold, G., Köllermann, M. W., Oberneder, R., Schlimok, G., Riethmüller, G., & Pantel, K. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2701 · Cited by 277 · cited 1×
“Substantial differences in final yield can occur if there are minor variations in reaction components and thermal cycling conditions and/or mispriming events during PCR [57–61].”
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248 · cited 1×
“AUCs for CgA have ranged as high as 0.8–0.9 in other studies [50,51], but this is A) The sensitivity and specificity of the test to detect GI-NENs (90%, 94”
InfluentialYao, J. C., Pavel, M., Phan, A. T., Kulke, M. H., Hoosen, S., St. Peter, J., Cherfi, A., & Öberg, K. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0666 · Cited by 225 · cited 2×
“Currently, CgA is used to evaluate treatment protocols [4,46] as expression levels are considered to relate to tumor burden [46].”
A comparison between three commercial kits for chromogranin A measurements
Stridsberg, M., Eriksson, B., Oberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 202 · cited 5×
“Measurements are thus not only mono-dimen-sional but not readily comparable if different assays utilizing different antibodies are used [29,30,33].”
InfluentialLapuk, A. V., Wu, C., Wyatt, A. W., McPherson, A., McConeghy, B. J., Brahmbhatt, S., Mo, F., Zoubeidi, A., Anderson, S., Bell, R. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4047 · Cited by 196 · cited 1×
“The existence of tumors with a significant neuroendocrine component e.g., prostate tumors [74] or colorectal cancers [75,76], provides additional clinical samples in which to evaluate the efficacy of the PCR test.”
Arnold, R., Wilke, A., Rinke, A., Mayer, C., Kann, P. H., Klose, K., Scherag, A., Hahmann, M., Müller, H., & Barth, P. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.052 · Cited by 192 · cited 2×
“To assess the efficacy of this signature index, we then compared it to CgA which is the current NEN marker used to establish diagnosis and disease status [30,42–46].”
WU, D. Y., UGOZZOLI, L., PAL, B. K., QIAN, J., & WALLACE, R. B. (1991) · DNA and Cell Biology · doi:10.1089/dna.1991.10.233 · Cited by 192 · cited 2×
“A consistent protocol for RNA isolation, cDNA synthesis and real-time PCR is considered appropriate to provide a stable platform for target and housekeeping gene analyses [57,62,63,66,67].”
Ding, C., & Cantor, C. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630494100 · Cited by 180 · cited 1×
“In other studies, this has been demonstrated to have a low variability between runs ranging between 0–5% [62], have small coefficient of variations (CVs) for the cycling threshold (CT) of 1–3% [63] and results in acceptable CVs for normalized data between 10–24% [64,65].”
Van der Auwera, I., Peeters, D., Benoy, I. H., Elst, H. J., Van Laere, S. J., Prové, A., Maes, H., Huget, P., van Dam, P., Vermeulen, P. B., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605472 · Cited by 174
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
Leja, J., Essaghir, A., Essand, M., Wester, K., öberg, K., Tötterman, T. H., Lloyd, R., Vasmatzis, G., Demoulin, J.-B., & Giandomenico, V. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.174 · Cited by 160
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study
Zatelli, M. C., Torta, M., Leon, A., Ambrosio, M. R., Gion, M., Tomassetti, P., De Braud, F., Delle Fave, G., Dogliotti, L., Uberti, E. C. D., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0001 · Cited by 159 · cited 2×
“Measurements are thus not only mono-dimen-sional but not readily comparable if different assays utilizing different antibodies are used [29,30,33].”
k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction
Parry, R. M., Jones, W. D., Stokes, T. H., Phan, J. H., Moffitt, A. B., Fang, H., Shi, L. M., Oberthuer, A., Fischer, M., Tong, W., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.56 · Cited by 155
Chromogranin A in uremia: Progressive retention of immunoreactive fragments
Hsiao, R. J., Mezger, M., & O’Connor, D. T. (1990) · Kidney International · doi:10.1038/ki.1990.71 · Cited by 146 · cited 1×
“These include non endocrine neoplasia (pancreatic and prostate) and a wide variety of cardiac, endocrine and inflammatory diseases [47], as well as in patients undergoing acid suppressive therapy with the proton pump inhibitor (PPI) class of drugs [48] and in renal failure [49].”
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
Mead, R. J., Duku, M., Bhandari, P., & Cree, I. A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.230 · Cited by 135 · cited 1×
“In comparison to other molecular-based tests, the performance metrics for the NEN-PCR-based test are substantially higher than for prostate (PSA or PMSA (0.75, both single target test) [52] or colon cancer (0.51–0.72, a two target PCR test) [53].”
InfluentialVischioni, B., Oudejans, J. J., Vos, W., Rodriguez, J. A., & Giaccone, G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0301 · Cited by 126 · cited 1×
“, chromogranin A/B (CHGA/CHGB: secretion], glutamate decarboxylase 1 [GAD1: GABA production] [25] and Aurora kinase B [AURKB: mitosis] [35] was undertaken.”
Keilholz, U., Willhauck, M., Rimoldi, D., Brasseur, F., Dummer, W., Rass, K., de Vries, T. J., Blaheta, J., Voit, C. A., Lethé, B., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10105-8 · Cited by 118 · cited 1×
“Stringent quality control [68], standardization of sample acquisition [69] and processing [70] therefore are a prerequisite for use of this molecular tool which makes it likely that any PCR approach will require dedicated, specialized facilities.”
Kidd, M. S., Modlin, I. M., Mane, S., Camp, R. L., Eick, G. N., & Latich, I. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.12.011 · Cited by 116
Self-citationGiusti, M., Sidoti, M., Augeri, C., Rabitti, C., & Minuto, F. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500299 · Cited by 111 · cited 1×
“These include non endocrine neoplasia (pancreatic and prostate) and a wide variety of cardiac, endocrine and inflammatory diseases [47], as well as in patients undergoing acid suppressive therapy with the proton pump inhibitor (PPI) class of drugs [48] and in renal failure [49].”
Nebozhyn, M., Loboda, A. P., Kari, L., Rook, A. H., Vonderheid, E. C., Lessin, S. R., Berger, C. L., Edelson, R. L., Nichols, C., Yousef, M., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2813 · Cited by 108 · cited 1×
“[41].”
Ippolito, J. E., Xu, J., Jain, S., Moulder, K., Mennerick, S., Crowley, J. R., Townsend, R. R., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500756102 · Cited by 107 · cited 1×
“These processes are consistent with the known biology of GEP-NENs [25].”
Classification of Dukes' B and C colorectal cancers using expression arrays
Frederiksen, C. M., Knudsen, S., Laurberg, S., & Ørntoft, T. F. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0434-x · Cited by 95 · cited 1×
“Intheformer,this isusedinprognosis,identificationofmetastasisandrecurrence, predictionoftherapyresponseandmetastasis-freesurvivalfornode-negative,untreatedprimarycancers[6,7];forthelatter,utilityhas beendeterminedforstaging[8].”
Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer
Aggarwal, A., Guo, D. L., Hoshida, Y., Yuen, S. T., Chu, K., So, S. K., Boussioutas, A., Chen, X., Bowtell, D. D. L., Aburatani, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2232 · Cited by 92 · cited 1×
“These included gene co-expression network profiling and functional gene community detection, all robust methods previously used in the development of gene-based molecular protocols [34].”
GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR
Kidd, M. S., Nadler, B., Mane, S., Eick, G. N., Malfertheiner, M. V., Champaneria, M. C., Pfragner, R., & Modlin, I. M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00251.2006 · Cited by 81 · cited 3×
“PCR values were normalized to ALG9 ( DD C T ) [15], using the control group as the population control (calibrator sample).”
InfluentialSelf-citationBlood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer
Zander, T., Hofmann, A., Staratschek‐Jox, A., Claßen, S., Debey‐Pascher, S., Maisel, D., Ansén, S., Hahn, M., Beyer, M., Thomas, R. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0533 · Cited by 69
Predictive biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation
Alymani, N. A., Smith, M. D., Williams, D. J., & Petty, R. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.001 · Cited by 67 · cited 1×
“It has been noted that the majority of biomarker studies may not translate into clinically relevant tests [55].”
Drozdov, I. A., Kidd, M. S., Nadler, B., Camp, R. L., Mane, S., Hauso, Ø., Gustafsson, B. I., & Modlin, I. M. (2009) · Cancer · doi:10.1002/cncr.24180 · Cited by 62 · cited 3×
“RNA was hybridized on Affymetrix platforms [11,12] and analysis performed as described previously [17].”
Self-citationGenetic Differentiation of Appendiceal Tumor Malignancy
Modlin, I. M., Kidd, M. S., Latich, I., Zikusoka, M. N., Eick, G. N., Mane, S., & Camp, R. L. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000217617.06782.d5 · Cited by 56 · cited 1×
“We have previously evaluated tissue-derived gene markers for GEP-NENs [9–11] and demonstrated their utility for detecting NEN malignancy [12].”
Self-citationSaveanu, A., Muresan, M., Micco, C. D., Taïeb, D., Germanetti, A. L., Sebag, F., Henry, J.-F., Brunaud, L., Enjalbert, A., Weryha, G., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0175 · Cited by 52 · cited 1×
“Given the similarities in biology (i.e., expression of receptors, pathways involved in secretion, molecular pathways e.g., MEN-I) [71–73] between GEP-NENs and other NENs e.g., pheochromytomas or medullary thyroid cancers, it would be useful to assess whether the PCR test can accurately identify…”
Discovering cancer genes by integrating network and functional properties
Li, L., Zhang, K., Lee, J., Cordes, S., Davis, D. P., & Tang, Z. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-61 · Cited by 50 · cited 1×
“Subsequently, we retained genes with high network clustering coefficient ( $ 0.25), based upon their increased likelihood of an association with tumorigenesis [26].”
InfluentialCirculating tumour markers can define patients with normal colons, benign polyps and cancers
Mead, R. J., Bhandari, P., Duku, M., & Cree, I. A. (2011) · Gut · doi:10.1136/gut.2011.239301.4 · Cited by 49
Glotsos, D. T., Tohka, J., Σπυρίδωνος, Π. Π., Cavouras, D., & Nikiforidis, G. (2005) · International Journal of Neural Systems · doi:10.1142/s0129065705000013 · Cited by 48 · cited 1×
“SVM has been utilized to predict grading in astrocytomas [36] ( .”
Chou, W., Hung, Y., Hsu, J., Chen, J., Lu, C., Hwang, T., Rau, K., Yeh, K., Chen, T., & Sun, C. (2012) · Neuroendocrinology · doi:10.1159/000333853 · Cited by 46 · cited 1×
“AUCs for CgA have ranged as high as 0.8–0.9 in other studies [50,51], but this is A) The sensitivity and specificity of the test to detect GI-NENs (90%, 94”
InfluentialModlin, I. M., Gustafsson, B. I., Drozdov, I. A., Nadler, B., Pfragner, R., & Kidd, M. S. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0251-1 · Cited by 41 · cited 1×
“CgA was measured using the DAKO ELISA kit (K0025, DAKO North America, Inc., Carpinteria, CA) [20] in a set of 176 samples (controls: n = 95; GEP-NENs: n =81).”
Self-citationYates, D. R., Morgan Rouprêt, A., Drouin, S., Compérat, É., Ricci, S., Lacave, R., Sèbe, P., Cancel‐Tassin, G., Bitker, M., & Cussenot, O. (2012) · The Prostate · doi:10.1002/pros.22488 · Cited by 37 · cited 1×
“In comparison to other molecular-based tests, the performance metrics for the NEN-PCR-based test are substantially higher than for prostate (PSA or PMSA (0.75, both single target test) [52] or colon cancer (0.51–0.72, a two target PCR test) [53].”
InfluentialNamwongprom, S., Wong, F. C., Tateishi, U., Kim, E. E., & Boonyaprapa, S. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0123-y · Cited by 34 · cited 1×
“To assess the efficacy of this signature index, we then compared it to CgA which is the current NEN marker used to establish diagnosis and disease status [30,42–46].”
Jung, R., Ahmad‐Nejad, P., Wimmer, M., Gerhard, M., Wagener, C., & Neumaier, M. (1997) · PubMed · Cited by 34
Mattfeldt, T., Gottfried, H., Wolter, H., et al. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00496 · Cited by 28 · cited 1×
“90% accuracy), and prostatic carcinomas (74–80% accuracy) [37].”
A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia
Jianu, C. S., Fossmark, R., Syversen, U., Hauso, Ø., & Waldum, H. L. (2010) · Tumor Biology · doi:10.1007/s13277-010-0045-5 · Cited by 28 · cited 1×
“To assess the efficacy of this signature index, we then compared it to CgA which is the current NEN marker used to establish diagnosis and disease status [30,42–46].”
Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays
Ramachandran, R., Bech, P., Murphy, K. G., Dhillo, W. S., Meeran, K. M., Chapman, R., Caplin, M. E., Ghatei, M. A., Bloom, S. R., & Martin, N. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04319.x · Cited by 24 · cited 7×
“Measurements are thus not only mono-dimen-sional but not readily comparable if different assays utilizing different antibodies are used [29,30,33].”
InfluentialOptimized blood cell profiling method for genomic biomarker discovery using high-density microarray
Shou, J., Dotson, C. A., Qian, H., Tao, W. Y., Lin, C.-H., Lawrence, F., N'Cho, M., Kulkarni, N. H., Bull, C. M., Gelbert, L. M., et al. (2005) · Biomarkers · doi:10.1080/13547500500218583 · Cited by 23 · cited 1×
“RNA was hybridized on Affymetrix platforms [11,12] and analysis performed as described previously [17].”
Functional Genomics Assistant (FUGA): a toolbox for the analysis of complex biological networks
Drozdov, I. A., Ouzounis, C., Shah, A. M., & Tsoka, S. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-462 · Cited by 22
Self-citationBai, V. U., Hwang, O., Divine, G., Barrack, E. R., Menon, M., Reddy, G. P., & Hwang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034875 · Cited by 16 · cited 1×
“Given the utility of these latter cancer tests in clinical management [54], it is probable that application of this PCR multi-transcript measurement strategy to GEP-NENs will be similarly effective.”
Cited by
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Self-citationConsensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
Self-citationMarotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Metadata
- Authors
- Modlin, I. M., Drozdov, I., & Kidd, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-15
- Volume
- 8
- Issue
- 5
- Pages
- e63364
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2023481027
- Cited by
- 164
- References
- 63
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.